The practicality of vigorous lowering of systolic pressure in diabetes to Ͻ130 mmHg remains uncertain. Baseline blood pressure data from several recent trials indicate that, in diabetic subjects, there is nearly a fourfold excess in systolic pressure (the difference between baseline pressure and target pressure) over diastolic pressure with respect to the recommended systolic/diastolic target pressure of Ͻ130/80 mmHg. Additionally, systolic pressure was 2-3 mmHg higher and diastolic pressure was 1-3 mmHg lower in diabetic hypertensive than in nondiabetic hypertensive individuals, which adds ϳ4 mmHg to pulse pressure and also to the difference between the excess systolic and excess diastolic pressure. We attempted to force (titrate both systolic and excess diastolic pressure) systolic and diastolic blood pressure to Ͻ130/85 mmHg based on Joint National Committee VI guidelines in the setting of a clinical practice in 257 diabetic patients. Although target systolic pressure was attained in a third of this cohort, in 57% of the patients, the attained diastolic pressure was Յ70 mmHg. Patients with final diastolic pressure Ͻ70 mmHg were older, had a higher prevalence of coronary artery disease, and had higher initial systolic and pulse pressures. Review of achieved blood pressure in studies such as the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) indicates that a significant fraction of the diabetic subjects' diastolic pressure was also driven down to Ͻ70 mmHg or even Ͻ60 mmHg. Thus, attempted lowering of blood pressure to target systolic pressure is associated with inordinate lowering of diastolic pressure in a significant number of patients. Whether the benefits of tight systolic control to Ͻ130 mmHg outweigh the risks of excessive diastolic reduction, especially in older diabetic subjects or diabetic patients with coronary artery disease, remains unresolved.
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T he gradual shift in the treatment of hypertension in diabetes from the classic target pressure of Ͻ140/90 mmHg to tighter blood pressure control has been influenced by several large clinical trials that provided unequivocal evidence that more intensive lowering of arterial pressure in diabetes is both feasible (1) and effective in reducing cardiovascular morbidity (1-3). The U.K. Prospective Diabetes Study may have been the first to discern the unique advantage offered to diabetic subjects by effective antihypertensive treatment, by showing that the rate of stroke and death related to diabetes was lower in diabetic individuals whose blood pressure was reduced to 144/82 mmHg compared with patients subjected to less tight blood pressure control, whose achieved blood pressure was 154/87 mmHg (3). The Hypertension Optimal Treatment (HOT) study provided evidence that the treatment target in diabetes should indeed be moved downward, since the lowest rate of major cardiovascular events was observed in treated hypertensive diabetic patients in whom the goal diastolic pressure was Ͻ80 mmHg (2). Although these studies supported the intensification of antihypertensive therapy in diabetes, the feasibility of attaining the guideline actual target blood pressure of Ͻ130/85 or 130/80 mmHg has hardly been studied, especially with regard to systolic goals. Only in recent years, after the results of several observational studies in which systolic blood pressure was a stronger predictor of cerebro-and cardiovascular morbidity than diastolic blood pressure (5-7), has the treatment paradigm of hypertension shifted to systolic blood pressure (4). This new focus on systolic pressure was reinforced by the large World Health Organization/International Society of Hypertension meta-analysis (Blood Pressure Lowering Treatment Trialists' Collaboration), which indicated that achieved systolic blood pressure in clinical trials was the strongest predictor of the actual reduction in the rate of stroke and coronary events (8). Although the implications for diastolic pressure of tighter systolic control (e.g., Ͻ130 mmHg) in diabetic hypertensive patients are largely unstudied, the prediction that diastolic pressure might be reduced beyond the range seen in traditional standard practice appears reasonable. Such excessive diastolic pressure lowering may not be entirely inconsequential, in light of recent data from the Framingham study indicating that in the middle-aged and elderly, who comprise the majority of the type 2 diabetic population, risk for coronary heart disease increases with lower diastolic pressure at any level of systolic pressure Ͼ120 mmHg (9). This contention follows the footsteps of earlier reports linking low diastolic pressure in treated hypertensive patients with increased risk for myocardial infarction (10,11). In one report, the relative risk for myocardial infarction at an achieved diastolic pressure of 60 mmHg was twofold higher than that at 100 mmHg (11). In a recent secondary analysis of the International VerapamilTrandolapril Study (INVEST), which focused on hypertensive subjects with coronary artery disease, risk for first occurrence of all-cause death and nonfatal myocardial infarction was clearly increased for patients in whom the ontreatment diastolic pressure was Ͻ70 mmHg (12). Achieved diastolic pressure of 60 -70 mmHg led to nearly twofold higher risk, and the risk tripled for
achieved diastolic pressure of Յ60 mmHg (12). The same trend was also noted in a subanalysis of the diabetic subjects in the INVEST trial, in whom coronary event rate tended to increase once diastolic pressure dropped to Ͻ60 mmHg. These latter findings were limited, however, by the small number of subjects identified at the lowest diastolic pressure range (13) .
In the present report, we first analyze current data on diastolic pressure in diabetic hypertensive subjects. We then review the results of our own experience in attempted forced titration of both systolic and diastolic blood pressure to the Joint National Committee VI target level of Ͻ130/85 mmHg in diabetes. Finally, we place the outcome of this field intervention in the perspective of achieved diastolic pressure in recent large hypertension clinical studies, in which the final on-treatment blood pressure was closer to the recommended target pressure compared with earlier trials. Even with suboptimal control of systolic blood pressure, marked lowering of diastolic pressure to Ͻ70 mmHg appears an inevitable outcome in a significant fraction of intensively treated hypertensive diabetic patients.
DIASTOLIC PRESSURE IN
TYPE 2 DIABETES -In the general population, systolic blood pressure increases progressively with age, whereas diastolic blood pressure rises until ϳ60 years of age, after which it starts to decline (14, 15) . The age-related decline in diastolic pressure is presumed to result from early recoil of the pressure wave, which, because of increasing arterial stiffness and lack of proper large artery compliance, occurs earlier (i.e., during the systole rather than later on during the diastole, as seen in the young). Such shift of the initial reflection wave from the diastole to the systole increases systolic and decreases diastolic pressure. A recent crosssectional case-control study showed that type 1 diabetic subjects had a higher systolic blood pressure than nondiabetic control subjects in all age-groups, whereas diastolic blood pressure was higher in individuals Ͻ40 years of age but lower in individuals Ͼ45 years of age (16) . These findings in older type 1 diabetic subjects are consistent with the concept that, whereas aging affects systolic and diastolic pressure in a parallel manner in subjects with and without diabetes, the changes in systolic and diastolic pressure induced by arterial stiffening take place at a younger age in diabetes. Because the pathogenesis of large artery disease likely results, at least in part from hyperglycemia per se (17) , one might anticipate similar alterations in systolic and diastolic pressure in type 2 diabetes as well. Consistent with this notion is our previous cross-sectional study of 2,227 subjects with type 2 diabetes, showing that whereas the prevalence of systolic hypertension rises steadily with age in type 2 diabetes, the prevalence of diastolic hypertension does not (18) . Table 1 depicts baseline systolic and diastolic pressure from several large clinical trials in hypertension that recruited both diabetic (mostly type 2) and nondiabetic hypertensive subjects. There are several lessons to be drawn from these reported baseline data, compiling a total of 21,188 hypertensive diabetic and 62,712 nondiabetic individuals with high blood pressure.
First, there is a larger excess in systolic pressure than in diastolic pressure with respect to the recommended pressure goal of Ͻ130/80 mmHg. The "systolic gap," i.e., the difference between baseline systolic pressure and the target pressure of 129 mmHg (the highest (13,19 -26) , respectively, but the corresponding gap between the pretreatment diastolic pressure and the target pressure of 79 mmHg was only 18.2, 18.2, 5.5, 6.4, 4, and 5 mmHg, yielding an average (nonweighted) systolic over diastolic excess ratio of ϳ4. Because the desirable reduction in systolic pressure so markedly exceeds that of the required diastolic pressure lowering, and because selective drugs affecting systolic but not diastolic pressure are not available, forced downward titration of systolic to Ͻ130 mmHg can be expected to lower diastolic pressure to much less than 79 mmHg, at least in some patients.
One additional key finding reflected in Table 1 is that in most of the included studies, systolic pressure was 2-3 mmHg higher and diastolic pressure was 1-3 mmHg lower in diabetic hypertensive individuals than in nondiabetic hypertensive individuals. Although there are major differences among the trials with respect to age, ethnic and geographic spread, the presence of comorbidities, previous blood pressure lowering therapy, and patient selection, the finding of lower baseline diastolic pressure and higher systolic pressure is fairly consistent across these trials. This adds ϳ4 mmHg to pulse pressure and also to the difference between the systolic and diastolic gap in diabetic versus nondiabetic subjects, thus provid- ing further opportunity to induce exaggerated diastolic decline in diabetes in the course of drug treatment driven by a systolic goal paradigm.
ATTEMPTED FORCED TITRATION OF BLOOD PRESSURE TO <130/85 MMHG IN TYPE 2 DIABETIC HYPERTENSIVE SUBJECTS -We have previously reported the results of systematic implementation of Joint National
Committee VI guidelines in clinical practice by forced titration of both systolic and diastolic pressure in 257 consecutive patients with type 2 diabetes and hypertension to Ͻ130/85 mmHg (27) . The initial mean blood pressure for the entire cohort was 159/86 mmHg, reflecting the fact that the majority of patients were already receiving blood pressure-lowering therapy at baseline and that the diastolic gap (extent of diastolic reduction required to achieve the target of 79 mmHg) was much lower than the systolic gap. Indeed, the latter was quite in line with baseline data in the large clinical trials reviewed above. We used individually tailored treatment, driven only by target levels, generally accepted preference principles, patients' ability to comply, and the appearance of clinical or biochemical adverse effects. Treatment was unbound to specific drug class or sequence, except for the use of ACE inhibitors whenever possible. Additionally, we did not further increase medication once diastolic blood pressure has reached 50 mmHg. After treatment, diastolic target pressure was achieved in 90% of patients (232/257). However, goal systolic pressure of Ͻ130 mmHg was reached in only one-third of this cohort (86/ 257) and the desirable systolic and diastolic pressure was observed in just 32% of the treated subjects. Nevertheless, despite this apparent high failure rate with respect to systolic target, the mean achieved systolic pressure in the entire cohort was 132 Ϯ 1 mmHg. Because systolic control so clearly lagged behind diastolic control, attempts to reach target systolic level in the presence of already normalized diastolic pressure resulted in lowering of diastolic pressure to Յ70 mmHg in 57% (146/257) of our patients (mean achieved diastolic pressure:
66 Ϯ 0.5 mmHg) and to Ͻ70 mmHg in about one-fifth of the cohort (53/257; mean achieved diastolic pressure: 60 Ϯ 1 mmHg). Of particular importance was the finding that patients with the lowest achieved diastolic pressure (Ͻ70 mmHg) had a nearly twofold higher prevalence of preexisting ischemic heart disease (52 vs. 27% in patients with on-treatment diastolic pressure of Ն70 mmHg. Low achieved diastolic pressure (Ͻ70 mmHg) was also associated with older age and high initial systolic pressure and initial pulse pressure (Fig. 1) . Additionally, in a forward multiple stepwise regression analysis, 52% of the variation in the attained reduction in diastolic pressure could be explained by the combination of initial systolic blood pressure (20%; ␤ coefficient 0.789; P Ͻ 0.0001), age (18%; ␤ coefficient 0.857; P Ͻ 0.0001), weight (2%; ␤ coefficient Ϫ0.1; P Ͻ 0.013), preexisting ischemic heart disease (1%; ␤ coefficient 2.72; P Ͻ 0.03), and the interaction between age and initial pulse pressure (11%; ␤ coefficient Ϫ0.01; P Ͻ 0.0001). Neither the attained diastolic pressure nor the actual decline in diastolic pres- sure was associated with the use of any specific antihypertensive drug class or a definable combination of drugs. These results support the concept that excessive lowering of diastolic pressure appears an inevitable outcome of attempts to approach the target systolic pressure.
RECENT EVIDENCE FOR DIASTOLIC COST IN LARGE CLINICAL TRIALS OF HYPERTENSION IN TYPE 2
DIABETIC SUBJECTS -The continuous failure to approach recommended systolic target values (Table 2) appears to be changing in recent trials, such as ALLHAT (24) and the AngloScandinavian Cardiac Outcomes TrialBlood Pressure Lowering Arm (ASCOT-BPLA) (28) , probably because of the inclusion of multiple dose adjustments and the combined use of multiple drugs. The resulting on-treatment systolic blood pressure in these studies has moved to the mid-130 mmHg zone, and not surprisingly, the attained mean diastolic pressure has inevitably shifted from the mid-80s all the way to 74 mmHg in ALLHAT. One overlooked aspect of this lower ontreatment mean diastolic pressure, which is best exemplified in ALLHAT, is depicted in Fig. 2 . If 1 SD is subtracted from the achieved mean diastolic pressure observed in the fifth and final year of ALL-HAT, the derived (mean Ϫ 1 SD) diastolic value is 65 mmHg for the chlorthalidone arm and 64 mmHg for either the amlodipine or the lisinopril arm. The parallel diastolic values reflecting 2 SDs below the mean would be 53-54 mmHg. Although less extreme, similarly low attained Ϫ1 SD/Ϫ2 SD diastolic pressure levels are obtained, even for the LIFE and ASCOT-BPLA studies (Fig. 2) . Because a nonnegligible part of treated hypertensive diabetic subjects in these studies must have fallen within the diastolic zone ranging between Ϫ1 SD and Ϫ2 SD, it follows that diastolic lowering to Ͻ70 mmHg and even to 50 -60 mmHg was recorded in a significant fraction of patients. This conclusion is certainly in line with our own experience in clinical practice summarized above. To our knowledge, the only instance in which target systolic pressure has been indeed achieved without excessive diastolic lowering is one of the ABCD trials (26) , conducted in diabetic subjects with mild hypertension, whose mean baseline blood pressure was 135/84 mmHg.
CONCLUSIONS -Therapeutically induced "diastolic hypotension" in diabetes may pose a previously unrecognized clinical challenge simply because the potential to implement current guidelines is increasing because of the effectiveness of current multi-drug combination therapy (32, 33) . Since it is generally accepted that most intramural coronary perfusion occurs in the diastole, patients with coronary artery disease appear particularly vulnerable to reduction in perfusion pressure during the diastole (low diastolic pressure). Because coronary disease in diabetes is not only extremely common but also often undiagnosed, our finding that excessive diastolic lowering is more common in subjects with coronary artery disease may be of great concern. The choice between leaving systolic pressure above the desirable range and lowering diastolic pressure to ϳ60 mmHg or less may not be restricted to diabetic patients, but with the exception of renal failure, the requirement in existing guidelines to lower systolic pressure to Ͻ130 mmHg is presently limited to diabetes. As the prevalence of diabetes rises with age, the elderly diabetic subject and/or the diabetic patient with coronary artery disease emerge as the most likely candidates to exhibit very low diastolic pressure in the course of aggressive systolic pressure lowering to target.
We believe that until more information on the risk ratio of leaving systolic pressure Ͼ130 mmHg versus lowering diastolic pressure to Ͻ70 or Ͻ60 mmHg is available, qualifications concerning the attained diastolic pressure should be considered in future guidelines for target blood pressure in older diabetic subjects, particularly in the presence of coronary artery disease.
